Search Results - "Fischer, Hans Holger"

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer by Nitz, Ulrike A., Gluz, Oleg, Kümmel, Sherko, Christgen, Matthias, Braun, Michael, Aktas, Bahriye, Lüdtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Darsow, Maren, Krauss, Katja, Nuding, Benno, Thill, Marc, Potenberg, Jochem, Uleer, Christoph, Warm, Mathias, Fischer, Hans Holger, Malter, Wolfram, Hauptmann, Michael, Kates, Ronald E., Gräser, Monika, Würstlein, Rachel, Shak, Steven, Baehner, Frederick, Kreipe, Hans H., Harbeck, Nadia

“…PURPOSE To our knowledge, WSG-ADAPT-HR+/HER2– (ClinicalTrials.gov identifier: NCT01779206 ; n = 5,625 registered) is the first trial combining the 21-gene…”
Get full text

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR–): survival outcomes from a multicentre, open-label, randomised, phase 2 trial by Nitz, Ulrike, Gluz, Oleg, Graeser, Monika, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Braun, Michael, Augustin, Doris, Potenberg, Jochem, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, zu Eulenburg, Christine, Kates, Ronald, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Harbeck, Nadia, von Schumann, Raquel, Kuhn, Walther, Polata, Silke, Bielecki, Wojciech, Meyer, Ralf, Just, Marianne, Kraudelt, Susanne, Siggelkow, Wulf, Wortelmann, Heidi, Kleine-Tebbe, Anke, Leitzen, Lena, Kirchhof, Heidrun, Krabisch, Petra, Hackmann, John, Depenbusch, Reinhard, Gnauert, Karsten, Staib, Peter, Lehnert, Antje, Hoffmann, Oliver, Briest, Susanne, Lindner, Christoph, Heyl, Volker, Bauer, Leila, Uleer, Christoph, Mohrmann, Svjetlana, Viehstaedt, Nicole, Malter, Wolfram, Link, Theresa, Buendgen, Nana, Tio, Joke

“…Several de-escalation neoadjuvant strategies have been investigated to reduce the use of chemotherapy in HER2-positive early breast cancer using pathological…”
Get full text

Impact of RNA Signatures on pCR and Survival after 12-Week Neoadjuvant Pertuzumab plus Trastuzumab with or without Paclitaxel in the WSG-ADAPT HER2+/HR- Trial by Graeser, Monika, Gluz, Oleg, Biehl, Claudia, Ulbrich-Gebauer, Daniel, Christgen, Matthias, Palatty, Jenci, Kuemmel, Sherko, Grischke, Eva-Maria, Augustin, Doris, Braun, Michael, Potenberg, Jochem, Wuerstlein, Rachel, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, Zu Eulenburg, Christine, Kates, Ronald, Ni, Hua, Kolberg-Liedtke, Cornelia, Feuerhake, Friedrich, Kreipe, Hans Heinrich, Nitz, Ulrike, Harbeck, Nadia

“…To identify associations of biological signatures and stromal tumor-infiltrating lymphocytes (sTIL) with pathological complete response (pCR; ypT0 ypN0) and…”
Get full text

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results by Harbeck, Nadia, Gluz, Oleg, Christgen, Matthias, Kuemmel, Sherko, Grischke, Eva-Maria, Braun, Michael, Potenberg, Jochem, Krauss, Katja, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Stefek, Andrea, Fischer, Hans Holger, Pelz, Enrico, Graeser, Monika, zu Eulenburg, Christine, Kates, Ronald E., Wuerstlein, Rachel, Kreipe, Hans Heinrich, Nitz, Ulrike

“…Abstract only 503 Background: Optimal use of de-escalated, particularly chemotherapy(CT)-free, neoadjuvant regimens in HER2+ early breast cancer (EBC) is…”
Get full text

Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12‐week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials by Graeser, Monika, Schrading, Simone, Gluz, Oleg, Strobel, Kevin, Würstlein, Rachel, Kümmel, Sherko, Schumacher, Claudia, Grischke, Eva‐Maria, Forstbauer, Helmut, Braun, Michael, Christgen, Matthias, Adams, Jascha, Nitzsche, Henrik, Just, Marianne, Fischer, Hans Holger, Aktas, Bahriye, Potenberg, Jochem, Schumann, Raquel, Kolberg‐Liedtke, Cornelia, Harbeck, Nadia, Kuhl, Christiane K., Nitz, Ulrike

“…We evaluated the role of early response after 3 weeks of neoadjuvant treatment (NAT) assessed by ultrasound (US), magnetic resonance imaging (MRI) and Ki‐67…”
Get full text

Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer by Schneeweiss, Andreas, Loibl, Sibylle, Mamounas, Eleftherios P., Minckwitz, Gunter von, Mano, Max S., Untch, Michael, Huang, Chiun-Sheng, Rastogi, Priya, Conte, Pier Franco, D'hondt, Veronique, Redondo, Andres, Stamatovic, Ljiljana, Bonnefoi, Herve R., Castro Salguero, Hugo Raul, Fischer, Hans Holger, Wahl, Tanya A., Song, Chunyan, Blotner, Steven, Trask, Peter, Geyer, Charles E.

“…Abstract only 513 Background: The phase 3 KATHERINE (NCT01772472) study, met its primary endpoint by demonstrating significantly improved invasive disease-free…”
Get full text

Final analysis of WSG-ADAPT HER2+/HR- trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant dual blockade with trastuzumab + pertuzumab ± weekly paclitaxel in HER2+/HR- early breast cancer (EBC) by Nitz, Ulrike, Gluz, Oleg, Christgen, Matthias, Grischke, Eva-Maria, Augustin, Doris, Kümmel, Sherko, Braun, Michael Wilhelm, Potenberg, Jochem, Kohls, Andreas, Krauss, Katja, Stefek, Andrea, Schumacher, Claudia, Forstbauer, Helmut, Reimer, Toralf, Fischer, Hans Holger, Liedtke, Cornelia, Wuerstlein, Rachel, Kreipe, Hans Heinrich, Harbeck, Nadia

“…Abstract only…”
Get full text

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer by Nitz, Ulrike A, Gluz, Oleg, Kümmel, Sherko, Christgen, Matthias, Braun, Michael, Aktas, Bahriye, Lüdtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Schumacher, Claudia, Darsow, Maren, Krauss, Katja, Nuding, Benno, Thill, Marc, Potenberg, Jochem, Uleer, Christoph, Warm, Mathias, Fischer, Hans Holger, Malter, Wolfram, Hauptmann, Michael, Kates, Ronald E, Gräser, Monika, Würstlein, Rachel, Shak, Steven, Baehner, Frederick, Kreipe, Hans H, Harbeck, Nadia

“…To our knowledge, WSG-ADAPT-HR+/HER2- (NCT01779206; n = 5,625 registered) is the first trial combining the 21-gene expression assay (recurrence score [RS]) and…”
Get full text